Altamira Therapeutics Announces Closing Of Up To $12.0 Million Public Offering
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- <li /> $4 million upfront with up to an additional $8 million of aggregate gro ...
Vancouver3 天
Vancouver biotech inks $800M partnership with Novo Nordisk
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
BCBusiness3 天
UBC’s NanoVation Therapeutics inks US$600 million deal with Novo Nordisk
The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...
Pharmaceutical Technology3 天
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
Researchers identify potential new strategy to slow the development of liver fibrosis
A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...
News Medical5 天
Activation of PPARβ/δ-AMPK pathway shown to slow liver fibrosis development
A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical ...
Endovascular Today6 天
Delcath Systems Hepzato Kit for mUM Evaluated in Subgroup Analysis of FOCUS Trial
Delcath Systems, Inc. announced the presentation of new subgroup analysis data from the phase 3 FOCUS trial of Hepzato Kit (m ...
Le Lézard6 天
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO ...
Delcath Systems, Inc. , an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase 3 trial of ...